Drug or treatment

Fludarabine clinical trials

• 34Clinical trials
• 9Countries

Newest trials

All recruiting trials (34)

• EGFR/HER2 dual-target CAR-NK cells for recurrent or metastatic HNSCC

  This trial tests an allogeneic CAR-NK cell therapy that targets EGFR and HER2 in adults with recurrent or metastatic head and neck cancer that express both biomarkers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617805

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• Dual-target CAR-NK therapy against CLDN18.2 and HER2 for advanced stomach/GEJ cancer

  This trial will test an off-the-shelf, cord-blood-derived CAR-NK cell therapy that targets CLDN18.2 and HER2 in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed after at least two prior treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07551362

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant

  This tests whether adding venetoclax to standard fludarabine–melphalan conditioning helps people over 50 with AML or MDS who are having an allogeneic stem cell transplant.

  Recruiting at 18 sites Phase 3 First Affiliated Hospital of Zhejiang University · Fuzhou, Fujian and 17 other locations · NCT07396480

• Induction and consolidation using fludarabine, cytarabine, idarubicin, and venetoclax for acute myeloid leukemia

  This trial tests whether adding venetoclax to induction and consolidation chemotherapy (fludarabine, cytarabine, and idarubicin) helps adults 18–65 with newly diagnosed acute myeloid leukemia or high-blast myelodysplastic syndrome achieve deeper remissions than standard cytarabine/daunorubicin therapy.

  Recruiting Phase 2 OHSU Knight Cancer Institute · Portland, Oregon · NCT07228273

• Fludarabine dosing for children and young adults with B-cell acute lymphoblastic leukemia

  This trial will test whether pharmacokinetic (PK)-targeted fludarabine dosing before tisagenlecleucel CAR T-cell therapy helps children and young adults with relapsed or refractory B‑cell ALL more than standard fludarabine dosing.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · New York, New York and 7 other locations · NCT07223021

• Fludarabine with intermediate-dose total body irradiation and PTCy for adults having allogeneic stem cell transplant

  This trial will test whether fludarabine plus intermediate-dose total body irradiation followed by post-transplant cyclophosphamide improves one-year survival for adults (18–65) receiving allogeneic stem cell transplants for blood cancers.

  Recruiting Phase 2 Hackensack Meridian Health · Washington D.C., District of Columbia and 2 other locations · NCT07214688

• Thiotepa, busulfan, and fludarabine treatment for elderly patients with high-risk acute myeloid leukemia

  This study is testing a new treatment plan using thiotepa, busulfan, and fludarabine to see if it helps older patients with high-risk acute myeloid leukemia stay cancer-free after a stem cell transplant.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06869265

• Comparing two doses of melphalan for stem cell transplantation in leukemia patients

  This study is testing whether a lower or higher dose of melphalan helps adults with leukemia or myelodysplastic syndrome have better outcomes after stem cell transplantation.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 1 other locations · NCT06829472

• Intensity-modulated total marrow irradiation for high-risk blood cancers

  This study is testing a new type of radiation treatment combined with standard chemotherapy to see if it helps people with high-risk blood cancers feel better after receiving stem cell transplants.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06802315

• Comparing two conditioning regimens for haploidentical stem cell transplantation

  This study is testing two different treatment plans for patients getting stem cell transplants from partially matched donors to see which one works better in preventing complications like graft failure and relapse.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06477549

• Using a new antibody treatment with chemotherapy and radiation for high-risk blood cancers before stem cell transplant

  This study is testing a new antibody treatment combined with chemotherapy and radiation to see if it can help people with high-risk blood cancers before they receive a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06287944

• Finding the best dose of imetelstat with chemotherapy for children with certain blood cancers

  This study is testing the best dose of a new drug called imetelstat combined with chemotherapy to see if it can help children with tough blood cancers like leukemia and myelodysplastic syndrome.

  Recruiting at 18 sites Phase 1 Children's Oncology Group · Birmingham, Alabama and 18 other locations · NCT06247787

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• Intensive conditioning for myeloid cancers with extramedullary involvement

  This study is testing a new treatment plan using specific medications before a stem cell transplant to see if it helps people with myeloid cancers that have spread beyond the bone marrow feel better and have better outcomes.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06111612

• GVHD prevention with Thymoglobulin versus Grafalon in older adults with AML or MDS receiving a 10/10 matched unrelated donor transplant

  This trial tests whether Thymoglobulin or Grafalon better prevents graft-versus-host disease in people aged 50–70 with AML or MDS who are receiving a 10/10 HLA matched unrelated donor stem cell transplant.

  Recruiting at 26 sites Phase 3 Assistance Publique - Hôpitaux de Paris · Amiens and 27 other locations · NCT06083129

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• Comparing conditioning regimens for patients with acute myeloid leukemia or myelodysplastic syndromes

  This study is testing two different treatment plans for adults with acute myeloid leukemia or myelodysplastic syndromes to see which one helps prevent the disease from coming back after a stem cell transplant.

  Recruiting at 9 sites Phase 3 Shanghai Jiao Tong University School of Medicine · Fuzhou, Fujian and 8 other locations · NCT05991908

• Comparing two treatment regimens for adults with acute myeloid leukemia before stem cell transplant

  This study is testing if a treatment using Clofarabine helps adults with acute myeloid leukemia live longer after a stem cell transplant compared to another treatment with Fludarabine.

  Recruiting at 20 sites Phase 2 Nantes University Hospital · Nantes, Loire Atlantique and 22 other locations · NCT05917405

• Chemotherapy and Reduced Intensity Conditioning for Refractory Acute Myeloid Leukemia

  This study is testing a new treatment plan that combines a special chemotherapy with a gentler conditioning method to see if it helps people with hard-to-treat acute myeloid leukemia feel better and live longer.

  Recruiting at 3 sites Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 2 other locations · NCT05870995

• High-dose immunosuppressive therapy followed by stem cell transplantation for multiple sclerosis

  This study is testing if a high-dose treatment followed by stem cell transplantation can help people with multiple sclerosis who haven't had success with regular treatments.

  Recruiting Phase 1 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT05832515

• Using Venetoclax with FLAMSA and Treosulfan for Blood Stem Cell Transplantation in Certain Blood Cancers

  This study is testing if a new combination of medications can make blood stem cell transplants safer and more effective for people with certain serious blood cancers.

  Recruiting at 6 sites Phase 1/2 Heinrich-Heine University, Duesseldorf · Aachen, North Rhine-Westphalia and 5 other locations · NCT05807932

• Reduced intensity conditioning for older patients with myeloid malignancies

  This study is testing a gentler treatment plan for older patients with blood cancers to see if it helps them live longer and healthier after a stem cell transplant.

  Recruiting at 2 sites Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 1 other locations · NCT05436561

• Reduced toxicity conditioning for high-risk thalassemia treatment

  This study is testing a new transplant method to see if it can safely help children with high-risk thalassemia by reducing side effects and improving their chances of recovery.

  Recruiting Phase 1/2 The Hospital for Sick Children · Toronto, Ontario · NCT05426252

• Reduced intensity transplant protocol for hematologic malignancies

  This study is testing a gentler transplant method using a specific combination of medications and radiation to see if it helps patients with blood cancers who have a matched donor.

  Recruiting Northside Hospital, Inc. · Atlanta, Georgia · NCT05417971

• Donor stem cell transplant with chemotherapy and radiation for blood cancers

  This study is testing if a donor stem cell transplant combined with different doses of chemotherapy and radiation can help people with blood cancers recover better.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04195633

• Intensity Modulated Total Marrow Irradiation for Acute Leukemia and MDS

  This study is testing a new type of radiation treatment before a stem cell transplant to see if it helps people with acute leukemia or myelodysplastic syndromes do better.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT04187105

• Using donor stem cells with specific chemotherapy to treat non-cancerous blood disorders

  This study is testing a new treatment using donor stem cells and specific chemotherapy to see if it can help people with non-cancerous blood disorders feel better and improve their health.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03980769

• Allogeneic stem cell transplantation for relapsed T- and NK/T-cell lymphomas

  This study is testing a new, less harmful treatment using stem cell transplants for people with T- and NK/T-cell lymphomas that have come back or didn’t get better with other treatments.

  Recruiting at 2 sites Phase 2 Keimyung University Dongsan Medical Center · Busan and 1 other locations · NCT02859402

• Transplant for Patients with Fanconi Anemia Using Adjusted Chemotherapy

  This study is testing a new way to use lower doses of chemotherapy before a stem cell transplant to see if it can safely help people with Fanconi anemia and serious blood disorders.

  Recruiting at 2 sites Phase 2 Children's Hospital Medical Center, Cincinnati · New York, New York and 2 other locations · NCT02143830

• Combination chemotherapy for newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a mix of chemotherapy drugs to see if they can help people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome achieve remission and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT00801489

Quick answers

How many clinical trials of Fludarabine are recruiting right now?

34, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in United States (15 trials), China (11 trials), Germany (2 trials), France (2 trials), Russia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 17, Phase 1/2: 5, Phase 3: 5, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →